Authors:
Julia M. Berger (1)*, Pia Gattinger, PhD (2)*, Maximilian J. Mair, MD (1), Anna S. Berghoff, MD, PhD (1), Rudolf Valenta, MD (2), Matthias Preusser, MD (1)
Division of Oncology and Christian Doppler Laboratory for Personalized Immunotherapy, Department of Medicine I, Medical University of Vienna, Vienna, Austria
Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
*shared first authors
Corresponding Author:
Matthias Preusser, MD, Division of Oncology,
Department of Medicine I, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria (matthias.preusser@meduniwien.ac.at)
Word count: 579 (of 600)
Number of figures and tables: 2
Acknowledgements: We thank Hannah Puhr, MD, Dominikus Huber, MD, Cornelia Englisch, MD, Lynn Gottmann, Martin Korpan, and Markus Kleinberger for support with sample and data collection. None of these individuals received additional compensation for their contribution. Written permission to include these individuals in this section has been obtained.
Source(s) of support: This study was funded by the Austrian Federal Ministry for Digital and Economic Affairs; the National Foundation for Research, Technology and Development; and the Christian Doppler Research Association. This study was also funded from the research budget of the Medical University of Vienna. . The funding organizations had no role/influence in design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Conflict of Interest: Dr Mair reported receiving nonfinancial support from Pierre Fabre outside the submitted work. Dr Valenta reported receiving personal fees from Viravaxx AG and Worg Pharmaceuticals; receiving grants from HVD Biotech, Viravaxx AG, and Worg Pharmaceuticals outside the submitted work; and holding a patent for Molecular Interaction Assay (pending) and a patent for SARS-CoV-2 vaccine (pending). Dr Preusser reported receiving personal fees from Bayer, Bristol Myers Squibb, Novartis, Gerson Lehrman Group, CMC Contrast, GlaxoSmithKline, Mundipharma, Roche, BMJ Journals, MedMedia, AstraZeneca, AbbVie, Lilly, Medahead, Daiichi Sankyo, Sanofi, Merck Sharp & Dohme, Tocagen, Adastra, and Gan & Lee Pharmaceuticals outside the submitted work. No other disclosures were reported.